Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2014 Jun 13;24(1):75–85. doi: 10.1002/pds.3660

Figure 1. Timeline of observation periods for adherence and persistence of DM medication users a relative to breast cancer diagnosis date.

Figure 1

a. ≥1 Dispensing of metformin and/or sulfonylureas in the year prior to breast cancer diagnosis

b. Treatment period: SEER diagnosis date to 120 days post-final breast cancer treatment noted in the medical chart (surgery, radiation, or chemotherapy) plus 90 days